분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-12-20 13:04:01 , Hit : 367
 Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness

https://www.marketwatch.com/story/spark-therapeutics-shares-rise-on-fda-approval-of-new-gene-therapy-for-blindness-2017-12-19-1191742

Published: Dec 19, 2017 11:07 a.m. ET  

By Emma Court
Reporter

Spark Therapeutics Inc. ONCE, -0.22% shares rose 3% in heavy morning trade Tuesday after the company's gene therapy Luxturna was approved by the Food and Drug Administration for a rare type of inherited vision loss. Just one administration of the therapy could treat the disease, making it a major scientific breakthrough. The approval had been widely expected after an FDA committee recommended it in October, and was heralded by FDA Commissioner Scott Gottlieb as "another first in the field of gene therapy." The next, major question for the therapy is price, with some analysts projecting the cost could come close to $1 million. Gene therapies, the first of which was approved this past summer, are expected to challenge existing U.S. payment structures with their price tags, which are extremely high and cover a one-time treatment. Luxturna was approved for individuals with confirmed biallelic RPE65 mutation-associated retinal dystrophy, which is part of a group of eye disorders caused by gene mutations, can cause complete blindness in some cases and affects about 1,000 to 2,000 people in the U.S. Spark shares have plummeted 41.5% over the last three months, compared with a 7.2% rise in the S&P 500 SPX, -0.32% and a 10.8% rise in the Dow Jones Industrial Average DJIA, -0.15%







1067   CRISPR Efficiency Tied to Cancer-Causing Process  이성욱 2018/06/13 325
1066   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 325
1065   RNA World May Have Started Spinning with Triplet-Based Synthesis  이성욱 2018/05/21 289
1064   CRISPR’s MAGESTIC Evolution Makes Gene Editing More Precise  이성욱 2018/05/08 411
1063   CRISPR-Cas9 Improved 10,000-Fold by Synthetic Nucleotides  이성욱 2018/04/17 413
1062   Nature Methods retracts CRISPR study  이성욱 2018/04/10 595
1061   릴리 '시람자' 간암 말기 임상시험 성공  이성욱 2018/04/07 478
1060   Powerful enzyme could make CRISPR gene-editing more versatile  이성욱 2018/03/01 430
1059   Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals  이성욱 2018/02/01 609
1058   Shields Up for New Cancer Gene-Therapy Virus  이성욱 2018/02/01 510
1057   JPM서 논란 ‘유전자가위 기술’ 올해의 마일스톤은?  이성욱 2018/01/21 975
1056   암 면역요법, 일부 환자에게만 효과 있는 이유  이성욱 2018/01/12 585
1055   [바이오토픽] CRISPR 기반 유전자치료를 방해하는 면역계  이성욱 2018/01/10 587
1054   [미국] 2017년, 유전자가위 기술을 통한 네 가지 사건들  이성욱 2018/01/10 530
1053   Using Oncolytic Viruses to Boost Response to Immune Checkpoint Inhibitors  이성욱 2018/01/05 835
1052   Alcohol Boosts Cancer Risk by Damaging Stem Cell DNA  이성욱 2018/01/05 507
1051   [바이오토픽] Science, 2017년 과학연구 총결산  이성욱 2017/12/27 1003
1050   FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 508
  Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness  이성욱 2017/12/20 367
1048   작년 바이오산업 규모 8조8775억원, 투자 13.9% 늘어  이성욱 2017/12/13 487

[이전 10개] [1].. 11 [12][13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN